Literature DB >> 19360348

Down-regulation of hTERT expression plays an important role in 15-deoxy-Delta12,14-prostaglandin J2-induced apoptosis in cancer cells.

Mikako Moriai1, Naoki Tsuji, Daisuke Kobayashi, Kageaki Kuribayashi, Naoki Watanabe.   

Abstract

The cyclopentenone prostaglandin 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) has been shown to possess antineoplastic activity in human cancers of various origins. However, the mechanism of the antineoplastic activity of 15d-PGJ2 remains to be completely elucidated. It has been reported that inhibiting the expression of human telomerase reverse transcriptase (hTERT), a major determinant of telomerase activity, induces rapid apoptosis in cancer cells. In this study, we investigated the effect of 15d-PGJ2 on hTERT expression. Treatment with 30 microM 15d-PGJ2 for 72 h induced apoptosis in the colon cancer cells LS180. 15d-PGJ2 treatment decreased hTERT protein expression in a dose-dependent manner. Down-regulation of hTERT expression by hTERT-specific small inhibitory RNA induced apoptosis. These results indicate that the down-regulation of hTERT expression by 15d-PGJ2 plays an important role in its proapoptotic properties. Since 15d-PGJ2 reduced hTERT mRNA expression, we examined the effect of 15d-PGJ2 on the DNA-binding activity of c-Myc, specificity protein 1 (Sp1) and estrogen receptor (ER) to the hTERT gene promoter using an electrophoretic mobility shift assay. 15d-PGJ2 attenuated the DNA-binding of all three transcriptional factors. Further, we observed that 15d-PGJ2 inhibited the DNA binding of these factors by different mechanisms; suppressed c-Myc mRNA expression, enhanced Sp1 protein degradation via the ubiquitin-proteasome pathway and inhibited ERbeta phosphorylation at serine residues. We conclude that hTERT down-regulation by 15d-PGJ2 plays an important role in its proapoptotic properties. Furthermore, 15d-PGJ2 inhibits the transcriptional activity of c-Myc, Sp1 and ER by three different mechanisms and results in the transcriptional repression of the hTERT gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360348

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.

Authors:  Anne R Diers; Brian P Dranka; Karina C Ricart; Joo Yeun Oh; Michelle S Johnson; Fen Zhou; Manuel A Pallero; Thomas M Bodenstine; Joanne E Murphy-Ullrich; Danny R Welch; Aimee Landar
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

2.  Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Authors:  Hei Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Kyu Hyun Park; Tae Soo Kim; Jin Ju Kim; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

3.  Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

Authors:  Farhat L Khanim; Rachel E Hayden; Jane Birtwistle; Alessia Lodi; Stefano Tiziani; Nicholas J Davies; Jon P Ride; Mark R Viant; Ulrich L Gunther; Joanne C Mountford; Heinrich Schrewe; Richard M Green; Jim A Murray; Mark T Drayson; Chris M Bunce
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

4.  Mitochondrial targeting of the electrophilic lipid 15-deoxy-Delta12,14-prostaglandin J2 increases apoptotic efficacy via redox cell signalling mechanisms.

Authors:  Anne R Diers; Ashlee N Higdon; Karina C Ricart; Michelle S Johnson; Anupam Agarwal; Balaraman Kalyanaraman; Aimee Landar; Victor M Darley-Usmar
Journal:  Biochem J       Date:  2010-01-27       Impact factor: 3.857

Review 5.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.